In Vivo Pharmacology CROs

8 contract research organizations in our directory list at least one of In Vivo Efficacy, Dose-Response Studies, Target Engagement, Xenograft Models, Syngeneic Models, PDX Models, Neurodegenerative Models, Pain Models or Behavioral Assessment, across 3 countries. 6 report GLP capability and 7 report AAALAC accreditation. Compare their species, services and accreditations below, and contact labs directly from their profiles.

8 CROs 6 GLP 7 AAALAC 3 countries

About In Vivo Pharmacology

In vivo pharmacology studies test whether a compound does what it was designed to do in a living system: engaging its target, moving a disease-relevant endpoint, and doing so at exposures that can be translated to a clinical dose. They sit between in vitro screening and IND-enabling toxicology, and their results usually decide which candidate moves forward.

The work covers efficacy studies in disease models (oncology xenograft, syngeneic and PDX models, neurodegeneration, pain and behavioral models), dose-response studies, and target engagement or receptor occupancy measurements, often with PK/PD sampling built in. For antibodies and other biologics, the model species must express a target the molecule actually binds, which can narrow the choice of model and lab considerably.

Model validation matters more than the model name. Two labs can offer the same model with very different baseline variability, positive-control history and endpoint methods, so ask for recent control data before comparing on price.

How to choose a preclinical CRO →

In Vivo Pharmacology CROs

Showing 8 CROs. Order rotates daily so no lab is permanently listed first.

Noble Life Sciences

US Verified GLP AAALAC

Preclinical CRO offering in vivo pharmacology, toxicology, and surgical services.

Behavioral Assessment Flow Cytometry Histology Pharmacokinetics qPCR Mouse Pig Rabbit Rat

NeuroBridge

CN Verified GLP AAALAC

NeuroBridge Biotechnology is a specialized preclinical research organization based in Guangzhou, China, focused on non-human primate (NHP) and pig disease models and exploratory non-GLP translational studies. We support…

Behavioral Assessment In Vivo Efficacy Neurodegenerative Models Target Engagement AAV Biodistribution Cynomolgus monkey Minipig Non-human Primate Rhesus monkey

ANEWCRO, LLC.

US Verified

ANEWCRO is a nonclinical contract research organization (CRO) dedicated to providing innovative solutions and support to the biopharmaceutical industry, biotech startups and academic institutions. With unlimited access…

In Vivo Efficacy Catheterization CNS Drug Delivery Dose Range Finding Electroretinography (ERG) Cynomolgus monkey

Biomere

US Verified AAALAC

Biomere (a JOINN company) is a preclinical CRO based in Worcester, MA. Services include non-GLP PK/PD, discovery toxicology, surgical services, disease models, and laboratory sciences. Surgical services include…

In Vivo Efficacy Neurodegenerative Models Xenograft Models AAV Biodistribution Bioanalysis Cynomolgus monkey Minipig Mouse Non-human Primate

Porsolt

FR Verified GLP AAALAC

Preclinical in vivo pharmacology with CNS/behavioral expertise and multiple disease models.

Behavioral Assessment Histology Pharmacokinetics Toxicology Mouse Rabbit Rat

Charles River Laboratories

US Verified GLP AAALAC

Global preclinical/clinical CRO with extensive safety assessment, pharmacology, and discovery services.

Behavioral Assessment Bioanalysis Histology Pharmacokinetics Surgery Cynomolgus monkey Dog Mouse Pig

Lovelace Biomedical

US Verified GLP AAALAC

Preclinical in vivo pharmacology and toxicology with aerosol/inhalation expertise.

Behavioral Assessment Bioanalysis Histology Pharmacokinetics Surgery Cynomolgus monkey Dog Mouse Pig

BIOQUAL

US Verified GLP AAALAC

Nonclinical CRO supporting infectious disease and other in vivo studies; bioanalysis and pathology support.

Behavioral Assessment Bioanalysis Histology Pharmacokinetics Surgery Cynomolgus monkey Dog Mouse Pig

Questions to ask when choosing an In Vivo Pharmacology CRO

  • Can you share historical and positive-control data for this model from the past year?
  • How are animals randomized, and are efficacy readouts scored blind to treatment?
  • Can PK and biomarker samples be taken from the same animals to build a PK/PD relationship?
  • How was group size chosen, and has a power calculation been done for the primary endpoint?
  • For biologics: has target cross-reactivity been confirmed in this species or strain?